Research
Hormonal
Intensive lifestyle interventions (caloric restriction and physical activity) can induce significant weight loss (5-10%) and improve glycemic control in type 2 diabetes, but long-term maintenance is difficult due to physiological counter-regulation (increased appetite/hormonal resistance).
Start with lifestyle changes (diet and exercise) as they are the foundation of treatment. Aim for 5-10% weight loss to improve health. Be aware that your body will fight back with increased hunger after you lose weight. If you struggle to maintain weight loss long-term, consider adding medications that help counteract this hunger.
GoodQualifiesHIGH confidence
Снижение массы тела на 5–10% ассоциируется с улучшением гликемического контроля... В исследовании Look AHEAD активное изменение образа жизни позволило достичь снижения веса на 8,6% в течение первого года... Однако к моменту окончания исследования через 9,6 лет отмечалось ускользание эффекта.
Why this rating
Based on large, long-term RCTs (Look AHEAD, DPP, DPS) cited in the review.
Source
Obesity and type 2 diabetes: can we find a compromised treatment solution?
G. R. Galstyan et al. · Diabetes Mellitus · 2017
DOI 10.14341/dm8726
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., Liraglutide 3.0mg) and SGLT2 inhibitors significantly reduce body weight and improve glycemic control in T2D patients, with GLP-1 agonists showing superior weight loss compared to other drug classes.Strong
- Insulin and Sulfonylureas cause weight gain in T2D patients, which exacerbates insulin resistance and creates a cycle requiring further treatment intensification.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →